Alpine Immune and AbbVie sign $865m immunology deal
Striving to Outsmart Cancer Together | AbbVie
AbbVie on Twitter: "Tom Hudson joined AbbVie to help bring innovative treatments to patients faster. Learn more about his vision for the future of cancer treatment via @CancerResearch: https://t.co/XdfWDnDzpd https://t.co/QM87UDuA0j" / Twitter
AbbVie on Twitter: "Tom Hudson, AbbVie Chief Scientific Officer How it started: How it's going: https://t.co/4o1roia3Yt" / Twitter
Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe | FiercePharma
AbbVie hits go on $1B re-upped Calico deal as the Google life science spinout continues I-O, neuro push | FierceBiotech
AbbVie signs immunotherapy deal with I-Mab worth $2bn - Pharmaceutical Technology
AbbVie's risankizumab improves symptoms of psoriatic arthritis in trials
John Sansone - Sales Representative - AbbVie | LinkedIn
AbbVie and Regenxbio ink $1.75 billion eye care collaboration
Dr. Thomas J. Hudson Net Worth (2022) | wallmine
Tom Hudson - PharmTech Focus
Major cash injection for Alphabet and AbbVie's R&D program
Partner Spotlight: Thomas Hudson - Cancer Research Institute (CRI)
Strategic Advisory Board
AbbVie: ChemBeads, Improving Artificial Intelligence Through Human Ingenuity
Our R&D Leaders - Our Science | AbbVie
AbbVie Makes Large Investment in Regenxbio's Gene Therapy for Retinal Diseases - Eyewire+
AbbVie developing COVID-19 therapy | Crain's Chicago Business
Our R&D Leaders - Our Science | AbbVie
AbbVie's drug shows improvement in psoriatic arthritis symptoms in trials
AbbVie Careers - Tom Hudson has six sisters, including a twin sister, who were all drawn to science careers. “There wasn't any pressure to be in this field,” Tom says. “My dad
AbbVie Helps to Advance Gene Therapy for Chronic Retinal Diseases
A collaboration between the IRIC and AbbVie facilitated by IRICoR featuring Dr. Tom Hudson - YouTube
70+ "Hudson, Ms" profiles | LinkedIn
AbbVie's Skyrizi nabs psoriatic arthritis nod, its 2nd, shortly after Rinvoq | FiercePharma
